Summary
CareDx (CDNA) is a Great Momentum Stock: Should You Buy?
Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Industry Outlook CareDx, BrightSpring and PACS
CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
CareDx Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 170 | $3,659.23 | $7,617.7 | $3,958.47 | 108.18% |
| BG Bart Gancher Intech Investment Management LLC | 13,781 | $256,017.31 | $643,572.7 | $387,555.39 | 151.38% |
| JM John Malone Amundi | 11,891 | $206,427.76 | $559,709.37 | $353,281.61 | 171.14% |
 Melissa Tiscareno Bradley & Co. Private Wealth Management LLC | 8,087 | $550,643.83 | $377,662.9 | -$172,980.93 | -31.41% |
 Joseph Castro Nuveen LLC | 152,509 | $2.79M | $7.18M | $4.39M | 157.32% |
CareDx Inc. (CDNA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CareDx Inc. ever had a stock split?
CareDx Inc. Profile
| Professional Services Industry | Industrials Sector | John Walter Hanna Jr. CEO | NASDAQ (NMS) Exchange | 14167L103 CUSIP |
| US Country | 763 Employees | - Last Dividend | - Last Split | 17 Jul 2014 IPO Date |
Overview
CareDx, Inc. is a pioneering company focused on the discovery, development, and commercialization of diagnostic solutions targeted at transplant patients and their caregivers, both within the United States and internationally. The company has established a strong presence in the market through its comprehensive portfolio of products designed to enhance the care and management of transplant recipients. Its offerings span across various transplant types, including kidney, heart, and lung transplants. Initially founded as XDx, Inc., the company underwent a rebranding to CareDx, Inc. in March 2014, marking a significant milestone in its evolution. Since its incorporation in 1998, CareDx, Inc. has been headquartered in South San Francisco, California, where it continues to push the boundaries of transplant diagnostics and patient care.
Products and Services
- AlloSure Kidney - This innovative donor-derived cell-free DNA (dd-cfDNA) solution is designed specifically for kidney transplant patients, aiming to provide critical insights into the health and viability of the transplanted organ.
- AlloMap Heart - A gene expression solution that serves heart transplant patients, AlloMap Heart aids in the non-invasive monitoring of the immune system’s response to the transplanted heart, offering valuable information for patient management.
- AlloSure Heart - Similar to its kidney-focused counterpart, AlloSure Heart is a dd-cfDNA solution tailored for heart transplant recipients, providing essential data on graft health.
- AlloSure Lung - This specialized dd-cfDNA solution is crafted for lung transplant patients, enabling precise monitoring of the transplanted lung’s condition.
- Olerup SSP - Utilizing sequence specific primer technology, Olerup SSP offers a method for typing human leukocyte antigen (HLA) alleles, a critical factor in transplant compatibility and success.
- QTYPE - Designed for precision in HLA typing, QTYPE enhances the accuracy of transplant compatibility assessments, facilitating improved outcomes.
- Ottr - A comprehensive transplant patient management software, Ottr streamlines the process of monitoring and managing transplant recipients’ care.
- AlloSeq Tx - Providing high-resolution HLA typing, AlloSeq Tx delivers enhanced precision in assessing compatibility between donors and recipients.
- AlloSeq cfDNA - A surveillance solution measuring dd-cfDNA in blood, AlloSeq cfDNA offers a non-invasive means to monitor transplant health.
- AlloSeq HCT - Targeted at stem cell transplant recipients, AlloSeq HCT is a chimerism testing solution that evaluates the level of integration of transplanted cells.
- Allocell - This surveillance solution monitors the engraftment and persistence of allogeneic cells in patients who have undergone cell therapy transplants, supporting long-term transplant success.
- XynQAPI - A cloud-based transplant quality management software, XynQAPI aids healthcare providers in tracking and improving transplant outcomes through data analytics and insights.
- AlloCare - A mobile app offering a patient-centric resource for transplant recipients, AlloCare provides tools and information to support post-transplant life and health.
Additionally, CareDx has fostered strategic partnerships, including a license agreement with Illumina, Inc. for the development and commercialization of next-generation sequencing (NGS) products and technologies, and with Cibiltech SAS for the commercialization of iBox software, which provides predictive analysis of post-transplantation kidney allograft loss.
